Systemic medicines with multiple active substances
Original notice title
Spain – Antibacterials for systemic use – Medicamentos con principios activos apremilast, nintedanib, eltrombopag, dalvabancina, pazopanib y asitinib
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
40 / 100
Risk factors
Submission deadline is only one month from notice publication, which may be tight for preparing required documentation.
Selection criteria and required documents are not described in the notice or provided documents, creating uncertainty a...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- EUR 3.8M estimated value
- Framework procurement
- Supplies contract
- 3 lots
- Duration 2 YEAR
- Supply of pharmaceutical products to the Murcia Health Service
- Framework agreement covering six active substances (apremilast, nintedanib, eltrombopag, dalbavancina, pazopanib, axitinib)
Show full summary
Framework agreement for the supply of six pharmaceuticals (apremilast, nintedanib, eltrombopag, dalbavancina, pazopanib, axitinib) to the Servicio Murciano de Salud (Murcia Health Service) in Spain. The framework is without further competition and covers 2 years with two possible 1-year extensions. Award is based on price (55%) and quality (45%).
Risks
Submission deadline is only one month from notice publication, which may be tight for preparing required documentation.
Selection criteria and required documents are not described in the notice or provided documents, creating uncertainty a...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Supplies contract for pharmaceutical products
Administrative
- Electronic submission required
- Language: Spanish
Award Criteria
Lot 1
Lot 2
Lot 3
Lot 4
Lot 5
Lot 6
Buyer
Location
Espinardo, ESP
Buyer profile
Identifier
41261690169929
Activity
General public services
Lots (6)
LOT-0001
Apremilast starter pack and maintenance
Supply of apremilast starter pack (4x10mg, 4x20mg, 19x30mg) and maintenance 30mg tablets.
EUR 3.8M
Estimated value
Location
Duration
Category
Award Criteria
Deadline
Award details
CRITERIOS EVALUABLES MEDIANTE CIFRAS O PORCENTAJES.
OTROS CRITERIOS OBJETIVOS.
Value note
Show original TED data
Original lot title
Apremilast pack inicio (4 comp 10 mg + 4 comp 20 mg + 19 comp 30 mg); Apremilast mantenimiento 30 mg
Original TED description
Apremilast pack inicio (4 comp 10 mg + 4 comp 20 mg + 19 comp 30 mg); Apremilast mantenimiento 30 mg
LOT-0002
Nintedanib capsules
Supply of nintedanib 100mg and 150mg capsules.
EUR 3.8M
Estimated value
Location
Duration
Category
Award Criteria
Deadline
Award details
CRITERIOS EVALUABLES MEDIANTE CIFRAS O PORCENTAJES.
OTROS CRITERIOS OBJETIVOS.
Value note
Show original TED data
Original lot title
Nintedanib 100 mg capsulas; Nintedanib 150 mg capsulas
Original TED description
Nintedanib 100 mg capsulas; Nintedanib 150 mg capsulas
LOT-0003
Eltrombopag all presentations
Supply of eltrombopag in all available presentations.
EUR 3.8M
Estimated value
Location
Duration
Category
Award Criteria
Deadline
Award details
CRITERIOS EVALUABLES MEDIANTE CIFRAS O PORCENTAJES.
OTROS CRITERIOS OBJETIVOS.
Value note
Show original TED data
Original lot title
Eltrombopag (Todas las presentaciones disponibles)
Original TED description
Eltrombopag (Todas las presentaciones disponibles)
LOT-0004
Dalbavancina 500 mg vial
Dalbavancina 500 mg vial
EUR 3.8M
Estimated value
Location
Duration
Category
Award Criteria
Award details
CRITERIOS EVALUABLES MEDIANTE CIFRAS O PORCENTAJES.
OTROS CRITERIOS OBJETIVOS.
LOT-0005
Pazopanib 200 mg oral; Pazopanib 400 mg oral
Pazopanib 200 mg oral; Pazopanib 400 mg oral
EUR 3.8M
Estimated value
Location
Duration
Category
Award Criteria
Award details
CRITERIOS EVALUABLES MEDIANTE CIFRAS O PORCENTAJES.
OTROS CRITERIOS OBJETIVOS.
LOT-0006
Axitinib (todas las presentaciones disponibles)
Axitinib (todas las presentaciones disponibles)
EUR 3.8M
Estimated value
Location
Duration
Category
Award Criteria
Award details
CRITERIOS EVALUABLES MEDIANTE CIFRAS O PORCENTAJES.
OTROS CRITERIOS OBJETIVOS.
Procurement Details
- Publication date
- 23 Jun 2026
- Languages
- Spanish
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 431328-2026
Documents (1)
Similar tenders
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
40 / 100
Risk factors
Submission deadline is only one month from notice publication, which may be tight for preparing required documentation.
Selection criteria and required documents are not described in the notice or provided documents, creating uncertainty a...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications